Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Research method for drug resistance mechanism of liver cancer drug lenvatinib

A technology for lenvatinib and lenvatinib resistance, which is applied in the field of research on the mechanism of liver cancer drug lenvatinib resistance, can solve the problems of lack of research on lenvatinib resistance markers, and achieve sufficient evidence and accuracy high effect

Active Publication Date: 2022-06-28
THE THIRD HOSPITAL OF HEBEI MEDICAL UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are few reports on lncRNA-mediated lenvatinib resistance, and there is a lack of relevant research exploring lenvatinib resistance markers

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Research method for drug resistance mechanism of liver cancer drug lenvatinib
  • Research method for drug resistance mechanism of liver cancer drug lenvatinib
  • Research method for drug resistance mechanism of liver cancer drug lenvatinib

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0055] The research method of the resistance mechanism of liver cancer drug lenvatinib, including the following steps,

[0056] S1: respectively construct Lenva-R (Lenvatinib-resistant, drug resistance index is 3.0) and Lenva-S (Lenvatinib-sensitive) liver cancer cells; Figure 1-3 shown, where, figure 1 Flow chart for the construction of Lenva-R and Lenva-S liver cancer cells, figure 2 are the relative cell viability comparison results of Lenva-R and Lenva-S liver cancer cells, image 3 The staining results of apoptotic cells of Lenva-R and Lenva-S liver cancer cells were compared. from Figure 1-3 It can be seen that compared with HepG2 cells of Lenva-S, Lenva-R cells have stronger proliferation ability and lower apoptosis rate (P<0.01).

[0057] Further, S2: screening new molecules related to lenvatinib resistance in liver cancer cells;

[0058] S201: Use high-throughput transcriptome sequencing technology to analyze the gene differences caused by lenvatinib resistanc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a method for researching the drug resistance mechanism of a liver cancer drug, which comprises the following steps of: S1, respectively constructing liver cancer cells with drug resistance and sensitivity of the liver cancer cells with drug resistance and sensitivity of the liver cancer cells with the drug resistance of the liver cancer cells with the drug resistance of the liver cancer cells with the drug resistance of the liver cancer cells; s2, analyzing gene difference caused by the drug resistance of the lenvatinib by utilizing a high-throughput transcriptome sequencing technology, analyzing LncRNAs of difference of two groups of liver cancer cells with the drug resistance of the lenvatinib and the sensitivity of the lenvatinib, and screening and analyzing the LncRNAs with remarkable high expression in the liver cancer cells with the drug resistance of the lenvatinib and the sensitivity of the lenvatinib; s3, detecting the level of the new molecule NRAV screened out in the step S2 in the liver cancer cells with drug resistance and sensitive to the lenvatinib by using an in-vitro method and an in-vivo method; and S4, analyzing the relationship between the NRAV and the drug resistance of the lenvatinib. According to the invention, new molecules related to the drug resistance of the lenvatinib in liver cancer cells are screened, the relationship between the NRAV and the treatment effect of the lenvatinib is explored, and a basis is provided for further exploring the drug resistance mechanism of the NRAV and the liver cancer drug lenvatinib and the application of the NRAV and the liver cancer drug lenvatinib in clinical diagnosis and treatment of the liver cancer.

Description

technical field [0001] The present invention relates to the technical field of liver cancer drug lenvatinib, in particular to a research method for the drug resistance mechanism of liver cancer drug lenvatinib. Background technique [0002] Hepatocellular carcinoma (HCC, referred to as liver cancer) is the most common malignant tumor of the liver, which is characterized by insidiousness, rapid progress, high malignancy, poor treatment effect and high chemoresistance rate. Nearly 70% of HCC patients are diagnosed at an advanced stage of the disease and are no longer suitable for curative treatment options. Lenvatinib-based targeted therapy is one of the first-choice drugs for patients with advanced HCC. It belongs to the class of quinoline carboxamides and is a novel oral multi-kinase inhibitor. The tumor effect has obvious advantages. At present, the clinical application of TKI has made some unresectable liver cancer patients downstage, and some patients even achieved clin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886G01N33/574
CPCC12Q1/6886G01N33/57438C12Q2600/158C12Q2600/106C12Q2600/118Y02A50/30
Inventor 赵彩彦徐小洁马路园刘文鹏赵倩范义泽王亚东申川霍楠李星宇宋枚芳丛瑞
Owner THE THIRD HOSPITAL OF HEBEI MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com